Table 5 Clinical PET studies using [18F]AlF-NOTA-PRGD2 (18F-Alfatide) and [18F]AlF-NOTA-E[PEG4-c(RGDfK)]2 (18F-Alfatide II)
Year | Study | No Participants | Outcome | References |
|---|---|---|---|---|
[18F]AlF-NOTA-PRGD2 (18F-Alfatide) | ||||
 2013 | Lung cancer | 9 | All tumours visualised | Wan et al. (2013) |
 2014 | Differentiated thyroid cancer (DTC) | 20 | Most lymph node metastases showed abnormal uptake of the radioconjugate, but the diagnostic value was inferior to [18F]FDG | Cheng et al. (2014) |
 2015 | Lung cancer | 26 | Successfully differentiated malignant lesions from hamartoma. Challenging to differentiate inflammatory or inflammatory pseudotumours from malignancy | Gao et al. (2015) |
 2016 | Advanced non-small cell lung cancer (NSCLC) | 18 | May predict short-term outcome of concurrent chemoradiotherapy in patients with advanced NSCLC | Luan et al. (2016) |
 2016 | Glioblastoma (GBM) | 25 | Visualisation of GBM and predictive of sensitivity to concurrent chemoradiotherapy as early as 3 weeks after treatment | Zhang et al. (2016) |
 2017 | Lymph node metastases in NSCLC | 13 | Highly sensitive, specific and accurate detection of metastatic lymph nodes for NSCLC patients | Zhou et al. (2017) |
 2019 | Esophageal Squamous Cell Carcinoma (ESCC) | 61 | No significant differences in uptake between 18F-Alfatide and [18F]FDG were observed, but may provide a complementary information about ESCC metastasis | Dong et al. (2019) |
 2019 | Response to apatinib | 38 | High uptake in tumours correlated with a better response to apatinib therapy and may be of predictive value | Li et al. (2019) |
[18F]AlF-NOTA-E[PEG4-c(RGDfK)]2 (18F-Alfatide II) | ||||
 2015 | Healthy Volunteers | 5 | Well tolerated with no serious adverse events | Yu et al. (2015) |
 2015 | Brain metastases | 9 | All brain lesions were visualised | Yu et al. (2015) |
 2015 | Bone metastasis | 30 | Sensitivity in osteoblastic metastases was low but significantly higher than for [18F]FDG | Mi et al. (2015) |
 2018 | Breast Cancer | 44 | Good performance but not superior to [18F]FDG in identifying breast cancer in this study. May have superiority in detecting strongly ER + ve and HER2-ve expression | Wu et al. (2018) |
 2018 | Lung cancer & Tuberculosis (TB) | 20 | The radioconjugate was able to differentiate between lung cancer and TB | Du et al. (2018) |